Abstract:Immune factors such as interferon‑ɣ and interleukin 4 belong to the group of cytokines that are dependent on type I/II receptors for their signal transmission. Upon activation, these receptors transmit their signal to the cell nucleus and, thus, modulate gene transcription via a signaling cascade consisting of Janus kinases (JAK). This family of four kinases (JAK 1, JAK 2, JAK 3, and tyrosine kinase 2 (TYK2)) subsequently activate members of the signal transducer and activator of transcription (STAT). This finding turned the JAK/STAT signaling pathway into a pharmacological target for the treatment of inflammatory diseases in which cytokines using type I/II receptors play a pathogenic role. In 2018, the European Medicines Agency (EMA) approved tofacitinib for the treatment of psoriatic arthritis. This was the first approval of a JAK/STAT pathway inhibitor for patients treated by dermatologists and rheumatologists. Since then, several new JAK inhibitors have been approved for dermatologic diseases such as atopic dermatitis, alopecia areata, vitiligo, and plaque-type psoriasis. In addition, JAK inhibitors are being investigated for the treatment of many other skin diseases. Thus, systemic JAK inhibitors complete the spectrum of immunotherapeutics with a broader immunological approach compared to monoclonal antibodies. The low molecular weight of JAK inhibitors enables the preparation of these drugs for both systemic and topical administration. Their utilization could represent a valuable alternative to topical steroids. The safety profile of JAK inhibitors must be taken into account. Possible long-term effects may become apparent in the next few years. This article describes both approved JAK inhibitors and relevant new JAK inhibitors that are promising candidates for approval as therapeutics in dermatology.

Prospects of Janus Kinase Inhibitors in the Treatment of Skin Diseases

The JAK-STAT Pathway and the JAK Inhibitors

Janus Kinase and Tyrosine Kinase Inhibitors in Dermatology: A Review of Their Utilization, Safety Profile and Future Applications

Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease

Targeting Janus Kinase (JAK) for Fighting Diseases: The Research of JAK Inhibitor Drugs

[Janus kinase inhibitors for skin disorders]

JAK Inhibitors: Prospects in Connective Tissue Diseases

JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects

Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach

Small-molecule inhibitors of protein kinase C, the Janus kinases (JAK) pathway and phosphodiesterases in the treatment of psoriasis

JAK‐inhibitors in dermatology – small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects

Synthesis and clinical application of small-molecule inhibitors of Janus kinase

JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis

[JAK inhibition in the treatment of inflammatory rheumatic diseases]

Prospects of Targeting JAK/STAT Signal Transduction Pathways for Vasculitis.

JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review

Current Application Status and Structure-Activity Relationship of Selective and Non-Selective JAK Inhibitors in Diseases

Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?

JAK inhibitors in rheumatology

Therapeutic inhibition of the JAK-STAT pathway in the treatment of inflammatory bowel disease

JAK inhibitors (JAKi): Mechanisms of action and perspectives in systemic and autoimmune diseases